Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Obexelimab by Zenas BioPharma (USA) for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Acquired (Autoimmune) Hemolytic Anemia. According...
Obexelimab by Zenas BioPharma (USA) for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Immunoglobulin G4-Related Disease (IgG4-RD). According...
ZB-004 by Zenas BioPharma (USA) for Autoimmune Disorders: Likelihood of Approval
ZB-004 is under clinical development by Zenas BioPharma (USA) and currently in Phase I for Autoimmune Disorders. According to GlobalData,...
Obexelimab by Zenas BioPharma (USA) for Multiple Sclerosis: Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase II for Multiple Sclerosis. According to GlobalData,...
ZB-002 by Zenas BioPharma (USA) for Rheumatoid Arthritis: Likelihood of Approval
ZB-002 is under clinical development by Zenas BioPharma (USA) and currently in Phase I for Rheumatoid Arthritis. According to GlobalData,...